consolidative radiotherapy for oligometastatic her2-negative esophageal and gastric adenocarcinoma.
Published 2 years ago • 196 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
0:54
targeted treatment for gastric cancer beyond her2
-
35:36
personalized treatment of advanced her2-negative gastric or gastroesophageal junction cancer
-
1:43
gasther2: trastuzumab for advanced gastric cancer
-
1:18
using radiotherapy to manage oligometastatic kidney cancer
-
1:56
immunotherapy: esophageal and gastric cancer
-
1:33
trf-val-cac-016 suppresses gastric cancer growth
-
2:25
adjuvant therapy for esophageal cancer
-
1:25
pd-1 and pd-l1 expression in esophageal and gastric cancer
-
0:52
immunotherapy treatment options gastric and esophogeal cancers
-
1:43
defining and classifying oligometastatic prostate cancer
-
20:50
standard-of-care, second-line, and future therapies for gej and esophageal adenocarcinoma
-
11:51
debate: what is the optimal therapy for gej cancers? - cross
-
1:31
treating esophageal and stomach cancer | dana-farber cancer institute
-
13:28
treatment of esophagus cancer
-
3:25
considerations for molecular testing for her2 gastric cancer
-
8:19
debate: does radiation therapy play a role in gastric cancer adjuvant therapy? - yes
-
3:05
pi3k inhibitors for the treatment of brain metastases in her2-negative breast cancer
-
1:18
key areas of unmet need in gastroesophageal cancers
-
2:59
clinical implications of her2 in gi cancers